Retatrutide vs Tirzepatide vs Semaglutide: 2026 Evidence & Regulatory Comparison
Semaglutide, tirzepatide and retatrutide are often grouped together in conversations about medical weight management, but they are not equivalent therapies and do not have the same regulatory status.
The short answer: semaglutide is a GLP-1 receptor agonist, tirzepatide activates GIP and GLP-1 receptors, and retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. As of August 2026, FDA states that retatrutide is not an FDA-approved drug and cannot be used in compounding under federal law. FDA explains the distinction here.
How do the three medications differ?
| Therapy | Receptor activity | Evidence status |
|---|---|---|
| Semaglutide | GLP-1 | FDA-approved products exist for specific indications |
| Tirzepatide | GIP + GLP-1 | FDA-approved products exist for specific indications |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational; not FDA approved |
The number of receptors targeted does not automatically determine which therapy is appropriate for an individual patient.
Tirzepatide vs semaglutide: what does the head-to-head evidence show?
The 2025 SURMOUNT-5 trial directly compared maximum tolerated doses of tirzepatide and semaglutide in 751 adults with obesity without type 2 diabetes.
At 72 weeks, mean body-weight change was -20.2% with tirzepatide and -13.7% with semaglutide. Gastrointestinal adverse events were the most common in both groups and occurred primarily during dose escalation. Read the PubMed record for SURMOUNT-5.
Those are group averages from a controlled trial, not a prediction of an individual patient’s outcome.
What is retatrutide?
Retatrutide is a triple hormone receptor agonist being studied for obesity and metabolic disease.
In a phase 2 obesity trial, retatrutide produced substantial dose-dependent weight reductions, which is why it has received significant attention. The phase 2 trial is indexed on PubMed.
However, clinical promise does not equal approval. FDA currently states that retatrutide cannot be used in compounding under federal law and has warned about marketing of unapproved retatrutide products.
What about compounded semaglutide and tirzepatide?
Compounded drugs are not FDA approved. FDA states that they should generally be used only when a patient’s medical need cannot be met by an FDA-approved drug.
The agency has also reported adverse events associated with compounded semaglutide and tirzepatide and warns about dosing errors, salt forms of semaglutide and improper refrigerated shipping.
Patients should understand whether they are receiving an FDA-approved product or a compounded medication and why that option is being considered.
Which option is “best” for weight loss?
There is no universal answer. A clinician may consider:
- BMI and weight-related medical conditions
- prior weight-management treatment
- diabetes status and glucose control
- gastrointestinal history
- gallbladder and pancreatic history
- other medications
- pregnancy plans
- tolerability and adherence
- access and cost
Axiom Healthspan’s weight-management pathway begins with an intake and clinical review so treatment can be matched to the individual rather than selected from a social-media comparison chart.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide at 72 weeks. That does not mean every individual will respond better to tirzepatide.
Is retatrutide available as a compounded medication?
FDA currently states that retatrutide cannot be used in compounding under federal law.
Are compounded GLP-1 medications FDA approved?
No. FDA does not review compounded drugs for safety, effectiveness and quality before marketing in the same way it reviews FDA-approved medications.
Do GLP-1 medications require medical supervision?
Yes. Appropriate prescribing, titration, side-effect management and monitoring are clinical decisions.
Bottom line
Semaglutide and tirzepatide have established clinical programs and FDA-approved products for specific indications. Retatrutide remains investigational. Comparisons should separate exciting trial data from what is legally and clinically available today.
Sources
- FDA — Concerns With Unapproved GLP-1 Drugs
- PubMed — SURMOUNT-5 Tirzepatide vs Semaglutide
- PubMed — Retatrutide Phase 2 Obesity Trial
- Axiom Healthspan — Health Optimization Programs
Educational information only and not medical advice. Treatment selection requires clinician evaluation.
